Premium Nahrungsergänzungsmittel | artgerecht

Renal Anaemia: Causes, Symptoms and Treatment

Renal anaemia is a form of blood deficiency caused by chronic kidney disease. Damaged kidneys produce insufficient erythropoietin, reducing red blood cell production and impairing oxygen transport.

Regular tips about health Regular tips about health

Things worth knowing about "Renal Anaemia"

Renal anaemia is a form of blood deficiency caused by chronic kidney disease. Damaged kidneys produce insufficient erythropoietin, reducing red blood cell production and impairing oxygen transport.

What is Renal Anaemia?

Renal anaemia is a condition of reduced red blood cell mass that develops as a direct consequence of chronic kidney disease (CKD). Healthy kidneys produce the hormone erythropoietin (EPO), which stimulates the bone marrow to generate red blood cells (erythrocytes). As kidney function declines, EPO production falls, leading to a deficiency of haemoglobin -- the protein responsible for carrying oxygen in the blood. Renal anaemia commonly appears when the glomerular filtration rate (GFR) drops below 60 ml/min and is nearly universal in patients receiving dialysis.

Causes

The primary cause of renal anaemia is insufficient EPO synthesis by the damaged kidneys. Additional contributing factors include:

Shortened red blood cell lifespan due to uraemic toxins that accumulate in kidney failure
Iron deficiency, often related to dialysis-related blood loss or reduced dietary absorption
Vitamin B12 and folate deficiency due to dietary restrictions or malabsorption
Chronic inflammation, which inhibits iron utilisation and erythropoiesis
Bone marrow suppression caused by secondary hyperparathyroidism, a common complication of CKD

Symptoms

The symptoms of renal anaemia reflect insufficient oxygen delivery to tissues and may be aggravated by the underlying kidney disease:

Pallor of the skin and mucous membranes
Persistent fatigue and exhaustion
Shortness of breath on exertion or at rest in severe cases
Palpitations or a rapid heartbeat
Dizziness and difficulty concentrating
Reduced exercise tolerance and overall quality of life
In severe cases: angina pectoris and worsening heart failure

Diagnosis

Diagnosis is based on blood tests. Key parameters include:

Haemoglobin (Hb): Values below 12 g/dl in women and below 13 g/dl in men indicate anaemia
Haematocrit: The proportion of red blood cells in total blood volume
Reticulocyte count: Young red blood cells reflecting bone marrow activity
Ferritin and transferrin saturation (TSAT): Markers of iron status
Erythropoietin level: Typically inappropriately low relative to the degree of anaemia
Vitamin B12 and folate
GFR and creatinine: Assessment of kidney function

Treatment

Erythropoiesis-Stimulating Agents (ESA)

ESAs are synthetic analogues of endogenous erythropoietin, including epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta. They are administered subcutaneously or intravenously to stimulate bone marrow red blood cell production. The treatment target is a haemoglobin level of 10 to 12 g/dl.

Iron Supplementation

Iron is essential for red blood cell production and is frequently deficient in CKD patients. Iron supplementation is often given alongside ESA therapy. In dialysis patients, intravenous iron is preferred as oral absorption is frequently inadequate.

HIF Prolyl Hydroxylase Inhibitors (HIF-PHI)

A newer class of oral agents -- including roxadustat, daprodustat, and vadadustat -- work by inhibiting the breakdown of the transcription factor HIF (hypoxia-inducible factor), which naturally triggers EPO production in response to low oxygen levels. This stimulates endogenous erythropoiesis without requiring injections.

Blood Transfusions

Transfusions are reserved for severe, symptomatic anaemia due to associated risks such as iron overload, infection transmission, and sensitisation against donor antigens.

Prognosis and Clinical Importance

Untreated renal anaemia significantly increases the risk of cardiovascular disease, hospitalisation, and mortality in CKD patients. Early and adequate treatment improves quality of life, reduces cardiovascular complications, and may slow the progression of kidney disease.

References

Kidney Disease: Improving Global Outcomes (KDIGO) - KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012, Update 2024). kdigo.org
Eschbach JW, Egrie JC, Downing MR et al. - Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New England Journal of Medicine, 1987; 316(2):73-78.
Babitt JL, Lin HY - Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 2012; 23(10):1631-1634.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category